Key features and details | |
Cat. No. | MABL-966 |
Name | Anti-CD44 mAbs |
Clone No. | AFD- F8:33 |
From | Recombinant Antibody |
Isotype | Engineer antibody |
Application | functional assay, therapeutic, ELISA, FC |
Species Reactivity | Human |
Basic Information | |
Specificity | This antibody is specific for CD44vRA, which is a CD44 derived from rheumatoid arthritis patients. CD44vRA contains an extra alanine. At higher concentration it will also bind to other isoforms of CD44. CD44 is cell-surface receptor that plays a role in cell-cell interactions, cell adhesion and migration, helping them to sense and respond to changes in the tissue microenvironment. |
Alternative Name | CDw44; Epican; Extracellular matrix receptor III; ECMR-III; GP90 lymphocyte homing/adhesion receptor; HUTCH-I; Heparan sulfate proteoglycan; Hermes antigen; Hyaluronate receptor; Phagocytic glycoprotein 1; PGP-1 |
UniProt | P16070 |
Immunogen | The original mouse antibody was raised by immunizing C57BL/6 mice with soluble CD44vRA. CD44vRA is a form of CD44, containing an extra alanine, derived from rheumatoid arthritis patients. |
Application Notes | To test the ability of the mouse version of this antibody to bind to CD44vRA, flow cytometry was preformed on Namalwa cells expressing different isoforms of CD44 (Golan et al, 2007; pmid:17383158). Further, it was used in ELISA preformed on different isotypes of the CD44 protein to assess the ability of this antibody to bind specific types of CD44; CD44vRA (CD44 from rheumatoid arthritis patients) was bound most strongly (Golan et al, 2007; pmid:17383158). Furthermore, flowcytometry was preformed to analyse apoptosis of synovial fluid cells. The mouse version of this antibody was used to induced apoptosis (Golan et al, 2007; pmid:17383158). It was administred to arthritic mice to reduce joint inflammation and induced apoptosis above the spontaneous level in the spleen of the mice (Golan et al, 2007; pmid:17383158). |
Antibody First Published | Golan et al. Expression of extra trinucleotide in CD44 variant of rheumatoid arthritis patients allows generation of disease-specific monoclonal antibody J Autoimmun. Mar-May 2007;28(2-3):99-113. PMID:17383158 |
Note on publication | Describes the generation of monoclonal antibodies (mAbs) that exclusively bind, at concentrations ranging from 2 to 100 microg/ml, to a modified CD44 variant (designated CD44vRA) expressed on synovial fluid cells from joints of rheumatoid arthritis (RA) patients. |
COA Information （For reference only, actual COA shall prevail） | |
Size | 100 μg Purified antibody. |
Concentration | 1 mg/ml. |
Purification | Protein A affinity purified |
Buffer | PBS with 0.02% Proclin 300. |
Concentration | 1 mg/ml. |
Storage Recommendation | Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C. |
